US and Japanese-Based Top 25 Global Pharmaceutical Companies Select Drug
Model Explorer(R) for Model-Based Product Profile Visualization
MOUNTAIN VIEW, Calif., April 2, 2008 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that two Top 25 global pharmaceutical companies have become customers for its Drug Model Explorer (DMX) software. Scientists in each of the customer's clinical pharmacology groups expect to use DMX to rapidly display and share model-based results, including quantitative assessments of the competitive treatment landscape, with global development colleagues. The DMX license agreements are the tenth and eleventh that Pharsight has signed with leading pharmaceutical and biotechnology companies in Europe, Japan and the United States.
DMX is a web-based software tool that allows clinical drug development teams to quickly and efficiently explore the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies. DMX results provide a database of model-based knowledge on drug properties that can be leveraged across development programs and between therapeutic areas. The newest DMX release, version 1.6, displays the chance that a modeled drug effect will meet a specific target profile, through additions to the software interface that present probabilistic results more prominently to support clinical development decision-making.
"Pharsight is pleased that our two newest customers recognize the
contribution that modeling and simulation, combined with the novel
visualization technology that DMX offers, can make to improv
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved